Your browser is no longer supported. Please, upgrade your browser.
Settings
SHPG Shire plc daily Stock Chart
SHPG [NASD]
Shire plc
Index- P/E64.41 EPS (ttm)2.76 Insider Own0.10% Shs Outstand301.46M Perf Week3.48%
Market Cap53.61B Forward P/E10.30 EPS next Y17.26 Insider Trans0.00% Shs Float181.89M Perf Month0.25%
Income603.50M PEG5.58 EPS next Q3.30 Inst Own23.20% Short Float0.60% Perf Quarter8.22%
Sales11.40B P/S4.70 EPS this Y-65.50% Inst Trans0.06% Short Ratio1.10 Perf Half Y-0.60%
Book/sh96.08 P/B1.85 EPS next Y14.89% ROA0.60% Target Price238.85 Perf Year-1.53%
Cash/sh1.80 P/C98.84 EPS next 5Y11.55% ROE1.30% 52W Range160.40 - 208.32 Perf YTD4.83%
Dividend0.91 P/FCF- EPS past 5Y-12.80% ROI2.10% 52W High-15.22% Beta1.63
Dividend %0.51% Quick Ratio0.50 Sales past 5Y22.30% Gross Margin66.50% 52W Low10.11% ATR2.62
Employees23906 Current Ratio1.00 Sales Q/Q121.80% Oper. Margin8.40% RSI (14)54.25 Volatility1.10% 1.32%
OptionableYes Debt/Eq0.79 EPS Q/Q7.20% Profit Margin2.90% Rel Volume0.41 Prev Close177.84
ShortableYes LT Debt/Eq0.69 EarningsMay 02 BMO Payout0.00% Avg Volume981.77K Price176.62
Recom1.70 SMA202.09% SMA500.02% SMA200-2.24% Volume361,043 Change-0.69%
Mar-09-17Initiated Liberum Buy
Dec-02-16Initiated Societe Generale Buy
Sep-26-16Downgrade HSBC Securities Buy → Hold
Jun-03-16Reiterated Jefferies Buy $223 → $262
May-26-16Initiated Stifel Buy $230
May-06-16Initiated Liberum Buy
Feb-26-16Initiated Cantor Fitzgerald Buy
Feb-10-16Upgrade RBC Capital Mkts Sector Perform → Outperform $240 → $240
Feb-10-16Initiated Guggenheim Neutral
Jan-15-16Upgrade BofA/Merrill Neutral → Buy
Jan-12-16Upgrade Credit Suisse Neutral → Outperform
Jan-12-16Reiterated RBC Capital Mkts Sector Perform $248 → $240
Nov-17-15Upgrade Leerink Partners Mkt Perform → Outperform $239
Nov-03-15Upgrade HSBC Securities Hold → Buy
Oct-26-15Reiterated RBC Capital Mkts Sector Perform $263 → $248
Oct-14-15Initiated Northland Capital Outperform $288
Sep-30-15Upgrade HSBC Securities Reduce → Hold
Aug-06-15Downgrade Exane BNP Paribas Outperform → Neutral
Jul-16-15Resumed Berenberg Buy
Apr-29-15Initiated Exane BNP Paribas Outperform
Apr-26-17 01:00AM  Shire Granted EU Conditional Marketing Authorisation for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism PR Newswire
Apr-25-17 03:48PM  ETFs with exposure to Shire Plc : April 25, 2017 Capital Cube
08:15AM  Blog Coverage Eli Lilly's Breast Cancer Drug Achieved its Primary Endpoint in Late Stage Trial Accesswire
07:00AM  Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference PR Newswire
Apr-24-17 01:00AM  Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI) PR Newswire
Apr-17-17 01:00AM  Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemophilia Worldwide PR Newswire
Apr-10-17 07:00AM  PatientsLikeMe and Shire Pharmaceuticals Collaborate to Study Rare Genetic Diseases Business Wire
Apr-06-17 08:22AM  Novartis Licenses ECF843 Eye Drops From Lubris Investopedia
Apr-04-17 11:12AM  Shire Plc : SHPG-US: Dividend Analysis : March 10th, 2017 (record date) : By the numbers : April 4, 2017 Capital Cube
Apr-03-17 01:48PM  SHIRE PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-30-17 04:41AM  INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan PR Newswire
Mar-28-17 04:50PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Mar-27-17 01:32PM  Shire: Can It Pay Down Debt? Barrons.com
Mar-23-17 05:03PM  Shire (SHPG) Rare Disease Drug Gets Fast Track Designation Zacks
Mar-22-17 10:27AM  Shire hTTP Drug Secures Fast Track Designation Investopedia
07:00AM  Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary Thrombotic Thrombocytopenic Purpura PR Newswire
Mar-21-17 09:55AM  Is Shire Stock a Good Choice for Value Investors Now? Zacks
Mar-16-17 07:14PM  Shire's (SHPG) Cinryze Label Expanded for Pediatric Use Zacks
10:40AM  Shires Cinryze Drug Gets EU Label Expansion Investopedia
02:00AM  Shire Receives European Approval for Label Extension of CINRYZE®(C1 inhibitor ) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE PR Newswire
Mar-13-17 02:50PM  Whats that thing on top of the Sanofi-Genzyme building anyway? at bizjournals.com
02:31PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Mar-10-17 04:25PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
01:20PM  Biogen Spinoff Takes Flight With Focus On Hemophilia Drugs
Mar-09-17 08:49AM  Coverage initiated on Shire plc by Liberum
Mar-07-17 12:48PM  European Stocks Mixed as Frankfurt Rises, Paris Falls
Mar-06-17 01:55PM  CUVITRU Data Demonstrate Improved Treatment Satisfaction Relative to Patients' Previous Immunoglobulin Therapy PR Newswire
Mar-03-17 12:34PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Mar-02-17 05:08PM  Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top
12:34PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
12:12PM  These 3 Big Pharma Stocks Are Exceptionally Cheap at Motley Fool
Mar-01-17 05:02PM  SHIRE PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Shire to Participate at the Cowen 37th Annual Healthcare Conference PR Newswire
Feb-28-17 01:04PM  SHIRE PLC Financials
09:55AM  Amicus Therapeutics Launches Galafold in UK at Investopedia
Feb-27-17 06:00AM  Drugmakers Eye $35B Market Amid Obesity Crisis at Investopedia
01:01AM  argenx announces extension of therapeutic antibody alliance with Shire GlobeNewswire
Feb-24-17 04:42PM  SHIRE PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
01:21PM  NASH Is Todd Hagopian's Top Biotech Sub-Sector For 2017 at Forbes
10:02AM  Patient Dies In Roche Hemophilia Study at Investopedia
08:15AM  Blog Coverage Novartis Gains Priority Review from the FDA for its Cancer Drug Zykadia as a Frontline Treatment for ALK-positive Non-Small Cell Lung Cancer Accesswire
07:17AM  CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism PR Newswire
Feb-23-17 09:20AM  Biotech Movers: Shire Rises on Encouraging Angioedema Results
04:11AM  New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease PR Newswire
02:00AM  Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases PR Newswire
Feb-22-17 04:56PM  SHIRE PLC Files SEC form 10-K, Annual Report
03:13PM  Momenta Tops Q4 Earnings, Shares Down on Warning Letter
11:55AM  Shire Plc :SHPG-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017
11:05AM  Momenta 4Q Net 60 Cents a Share at Investopedia
Feb-21-17 02:01PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
09:27AM  Shire Plc :SHPG-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017
Feb-20-17 09:57AM  3 Stocks to Invest in Big Pharma at Motley Fool
Feb-17-17 02:04PM  Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
01:50PM  Shire PLC 4Q Earnings, Revenue Beat Street at Investopedia
01:08PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Feb-16-17 04:28PM  Drugmaker Shire Tops Q4 Views; Stock Pops To Six-Week High
08:14AM  Shire beats Street 4Q forecasts
07:52AM  Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline PR Newswire
07:25AM  Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth
Feb-15-17 04:24PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
12:49PM  Amicus Therapeutics Updates Migalastat Drug at Investopedia
Feb-14-17 07:30AM  Shire to Highlight Advancements in Rare Genetic Diseases PR Newswire
Feb-08-17 10:04AM  Shire ViroPharma Sued By FTC Over Sham FDA Filings at Investopedia
Feb-07-17 04:05PM  FTC says Shire unit used illegal tactics to block generic competition at bizjournals.com
03:42PM  Shire Responds to U.S. Federal Trade Commission Civil Action PR Newswire
10:45AM  Hemophilia Drug Market Competitive Ramps Up at Investopedia
Feb-02-17 10:40AM  5 Drugmakers Battle Over the $10 Billion Hemophilia Market at Motley Fool
Feb-01-17 03:49PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
01:39PM  New Data From Shire Aim to Help Close the Diagnosis and Treatment Gap for People With Hemophilia PR Newswire
Jan-27-17 12:20PM  Keeley All Cap Value Fund Comments on Shire
Jan-26-17 08:25AM  Drug Giants May Benefit From China Drug Inclusion at Investopedia
Jan-25-17 01:10PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Jan-23-17 11:27AM  5 Stupendously Expensive Cancer Drugs at Motley Fool
Jan-20-17 05:50PM  Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA
Jan-19-17 10:00AM  Is Shire plc a Great Stock for Value Investors?
07:00AM  U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD PR Newswire
Jan-18-17 12:37PM  Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug
Jan-17-17 12:24PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Jan-13-17 11:56AM  FTSE 100 continues record run, rising for 14th day in a row at MarketWatch
Jan-12-17 02:34PM  KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market Opportunity'
02:00PM  Lawsuit accuses Shire of monopolizing market for ADHD drug at bizjournals.com
12:20PM  Drug makers, auto stocks yank European stocks lower for first time in 3 days at MarketWatch
Jan-11-17 08:23PM  PRESS DIGEST- Financial Times - Jan 12 Reuters
04:32PM  [$$] Shire to Pay $350 Million to Settle Dermagraft Kickback Allegations at The Wall Street Journal
02:45PM  Pharmaceutical company agrees to landmark settlement in Tampa federal court at bizjournals.com
01:40PM  Trump slams drug industry at press conference, sending biotech stocks tumbling at bizjournals.com
12:21PM  FTSE 100 logs 10th day of all-time highs at MarketWatch
Jan-10-17 01:17PM  Shire CEO: Our innovation score is very high
Jan-09-17 05:35PM  Martin Whitman Invests in Homebuilder in 4th Quarter
01:55PM  Merrimack Pharma to Sell Cancer Drugs for $1B at Investopedia
Jan-06-17 04:22PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
10:46AM  For Shire PLC (ADR) (SHPG) Securing Hemophilia Market With Long Acting Version Is Crucial at Insider Monkey
Jan-05-17 02:40PM  Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference at bizjournals.com
12:52PM  Cooperman's best ideas: 14 stock picks
12:03PM  Billionaire James Dinan Betting On These Stocks To Recover Losses at Insider Monkey
Jan-04-17 05:14PM  SHIRE PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
09:30AM  Shire to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-03-17 05:31PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Dec-30-16 06:17AM  Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded
Dec-28-16 10:18AM  Shire Gets FDA Approval for Label Expansion of Adynovate
Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.